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Abstract
Background
Compared to Caucasians, Chinese achieve a higher blood concentration of statin for a
given dose. It remains unknown whether this translates to increased risk of serious statinassociated adverse events amongst Chinese patients.
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Methods
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We conducted a population-based retrospective cohort study of older adults (mean age,
74 years) newly prescribed a statin in Ontario, Canada between 2002 and 2013, where
19,033 Chinese (assessed through a validated surname algorithm) were matched (1:3) by
propensity score to 57,099 non-Chinese. This study used linked healthcare databases.
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Findings
The follow-up observation period (mean 1.1, maximum 10.8 years) was similar between
groups, as were the reasons for censoring the observation period (end of follow-up, death, or
statin discontinuation). Forty-seven percent (47%) of Chinese were initiated on a higher than
recommended statin dose. Compared to non-Chinese, Chinese ethnicity did not associate with
any of the four serious statin-associated adverse events assessed in this study [rhabdomyolysis
hazard ratio (HR) 0.61 (95% CI 0.28 to 1.34), incident diabetes HR 1.02 (95% CI 0.80 to 1.30),
acute kidney injury HR 0.90 (95% CI 0.72 to 1.13), or all-cause mortality HR 0.88 (95% CI 0.74
to 1.05)]. Similar results were observed in subgroups defined by statin type and dose.

Conclusions
We observed no higher risk of serious statin toxicity in Chinese than matched non-Chinese
older adults with similar indicators of baseline health. Regulatory agencies should review
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available data, including findings from our study, to decide if a change in their statin dosing
recommendations for people of Chinese ethnicity is warranted.
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Chinese ethnicity is often associated with heightened drug sensitivity, likely due to genetic differences in drug metabolism and clearance [1, 2]. For this reason, the recommended doses of
many therapeutic drugs are lower for Chinese (and others of Asian ethnicity) living in Western
countries [3–5]. This recommendation extends to the use of statins, one of the most frequently
prescribed drugs in the world (global users projected to reach 1 billion) [6]. Statins are associated with several rare but serious adverse events in a dose-dependent manner, including rhabdomyolysis, new-onset diabetes, and possibly acute kidney injury [7–11]. Pharmacokinetic
studies have demonstrated that compared to Caucasians, Chinese achieve a higher blood concentration of statins for a given dose [12–14]. Based on this evidence, Health Canada and the
US Food and Drug Administration (FDA) currently list Asian ethnicity as a risk factor for
statin-induced rhabdomyolysis and recommend a lower starting and maximum dose of rosuvastatin in all Asians [15, 16]. However, it remains unclear whether Asians truly experience a
higher risk of serious statin toxicity compared to non-Asians in routine practice. Previous studies have demonstrated comparable statin safety and efficacy profiles between South Asians and
Caucasians living in Canada [17], while there is no clear consensus for East Asian populations
living in Western countries. People of Chinese origin comprise roughly 20% of the global population and represent one of the largest minority populations in North America [18, 19]. In
this population-based study in Ontario, Canada, we compared the risk of serious statin-associated adverse events in older adults of Chinese and non-Chinese origin.

Introduction

Methods
Study Design and Setting
We conducted a population-based, retrospective cohort study at the Institute for Clinical Evaluative Sciences (ICES) according to an established protocol approved by the Research Ethics
Board at Sunnybrook Health Sciences Centre (Toronto, Canada). Data on adults 66 years of
age and older between June 2002 and March 2013 were obtained and analyzed through linked
healthcare databases in the province of Ontario. Participant informed consent was not required
for this study as all patient information was anonymized and de-identified prior to analysis.
The province has about 13.6 million residents, 16% of whom are 65 years or older and have
universal coverage for prescription drugs, and 4.7% of whom self-identify as Chinese [18, 20].
The reporting of this study follows guidelines for observational studies (Table A in S1 File)
[21]. The date of the first prescription of a study statin served as the index date (also referred to
as the cohort entry date or the date of statin initiation).

Data Sources
We ascertained patient characteristics, drug use, covariate information and outcome data using
records from five databases. The Ontario Registered Persons Database contains demographic
and vital status information for all Ontario residents who have ever been issued a health card.
We used the Ontario Drug Benefit database to identify prescription drug use. This database
contains highly accurate records (error rate < 1%) for all outpatient prescriptions dispensed to
people aged 65 years or older [22]. We identified diagnostic and procedural information on all
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hospitalizations from the Canadian Institute for Health Information Discharge Abstract Database (CIHI-DAD). We obtained covariate information from the Ontario Health Insurance
Plan (OHIP) database, which includes fee-for-service health claims for inpatient and outpatient physician services. Finally, we identified new onset diabetes from the Ontario Diabetes
Database (ODD) [23]. We have previously used these databases to research adverse drug events
(including outcomes of statin toxicity and health services) [24–30]. We used International
Classification of Diseases, 9th revision (ICD-9; pre-2002) and 10th revision (ICD-10; post-2002)
codes to assess baseline comorbidities in the three years prior to the index date (Table B in S1
File). The codes we used to ascertain outcomes are detailed in Table C in S1 File, which lists
only ICD-10 codes as this was the only coding system in use during the follow-up period.

Classification by Chinese Ethnicity
We identified patients of Chinese and non-Chinese ethnicity using a list of 1,133 unique Chinese surnames prior to anonymization of linked healthcare data. This surname list was developed and validated in Ontario, and has a sensitivity of 80% and a positive predictive value of
92% in classifying individuals who self-identify as Chinese [31]. While people of other Asian
ethnicities are included in the non-Chinese group, the proportion is likely small as 77% of the
Ontario population does not belong to a visible ethnic minority [32].

Patients
We established a cohort of older adults (i.e. > 65 years) in Ontario, Canada, who initiated one
of three study statins (atorvastatin, rosuvastatin, or simvastatin). Other drugs in this class are
infrequently used in Ontario, comprising less than 6% of all statin prescriptions during the
study period. We excluded patients if they met any of the following criteria: (a) they were in
their first year of eligibility for prescription drug coverage (aged 65 years), to avoid incomplete
medication records; (b) they received a prescription for any statin (study or non-study) in the
180 days prior to the index date, to confirm new statin use; (c) they were without healthcare eligibility in the 3 years prior to index date (for reasons such as immigration), to ensure sufficient
data to assess baseline comorbidities, and (d) they had co-prescriptions for potent CYP3A4
inhibitors (protease inhibitors, chloramphenicol, and antifungals) in the 180 days prior to their
index date, to avoid possible statin toxicity from drug-drug interactions [33]. A patient could
enter the cohort only once. To select statin users with similar characteristics, Chinese were
matched 1:3 to non-Chinese on the following baseline characteristics: age (within two years),
sex, index date (same year), chronic kidney disease, coronary artery disease, statin type and
dose (high dose defined as 10 mg rosuvastatin, 20 mg atorvastatin, or 40 mg simvastatin;
other values were classified as low dose [8]), and the logit of the propensity score for the predicted probability of Chinese ethnicity (within 0.2 standard deviations). The propensity score
was derived from a logistic regression model containing 58 appropriately selected baseline variables [34] (Table 1). To measure baseline comorbidity, we used two scoring systems: the
Adjusted Clinical Group (ACG) score and the Charlson Comorbidity Index [35–37].

Outcomes
We examined four outcomes associated with statin toxicity as specified in previous studies [7,
10, 24–27, 29, 30]: hospitalization with rhabdomyolysis, incident diabetes, hospitalization with
acute kidney injury, and all-cause mortality (the diagnostic codes and their validity are presented in Table C in S1 File). For incident diabetes outcome, we excluded matched sets of
patients with evidence of baseline diabetes. We selected acute kidney injury as a potential
adverse event of statin toxicity based on a recent report [8]; while completing our study,
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Table 1. Characteristics of Chinese and non-Chinese at cohort entry.
Unmatched
Chinese

Non-Chinese

N = 20,598
(%)

N = 605,175
(%)

Matched

Standardized
Difference *

Chinese

NonChinese

N = 19,033
(%)

N = 57,099
(%)

Standardized
Difference *

Demographics
Age, mean ± SD

73.6 ± 6.3

73.8 ± 6.5

3%

73.3 ± 6.0

73.3 ± 6.0

0%

11,094 (54)

318,527
(53)

2%

10,260 (54)

30,780 (54)

0%

One
(lowest)

4,489 (22)

118,328
(20)

6%

4,025 (21)

12,075 (21)

0%

Two

4,919 (24)

127,257
(21)

7%

4,490 (24)

13,796 (24)

1%

Three
(middle)

3,923 (19)

119,207
(20)

2%

3,711 (19)

11,072 (19)

0%

Four

3,854 (19)

118,085
(20)

2%

3,622 (19)

10,752 (19)

1%

Five
(highest)

3,362 (16)

120,476
(20)

9%

3,185 (17)

9,404 (16)

1%

Rural Residence

162 (1)

87,397
(14)

53%

154 (1)

630 (1)

3%

Long-term Care Facility

483 (2)

13970 (2)

0.2%

402 (2)

827 (1)

5%

2002–2003

3,183 (15)

110,941
(18)

8%

3052 (16)

9,156 (16)

0%

2004–2005

3,663 (18)

120,927
(20)

6%

3,443 (18)

10,329 (18)

0%

2006–2007

4,007 (19)

110,266
(18)

3%

3,616 (19)

10,848 (19)

0%

2008–2009

3,838 (19)

106,714
(18)

3%

3,473 (18)

10,410 (18)

0%

2010–2011

3,962 (19)

102,268
(17)

6%

3,656 (19)

10,968 (19)

0%

2012

1,945 (9)

54,090 (9)

2%

1,796 (9)

5,388 (9)

0%

897 (4)

60,918
(10)

22%

822 (4)

2,332 (4)

1%

0

13,348 (65)

334,923
(55)

19%

12,443 (65)

36,689 (64)

2%

1

1,210 (6)

32,991 (5)

2%

1,120 (6)

3,573 (6)

2%

2

1,065 (5)

39,043 (6)

5%

9,72 (5)

3,287 (6)

3%

3

4,975 (24)

198,218
(33)

19%

4,498 (24)

13,550 (24)

0%

0

582 (3)

21,030 (3)

4%

565 (3)

1,933 (3)

2%

1

436 (2)

18,127 (3)

6%

423 (2)

1,638 (3)

4%

609 (3)

23,206 (4)

5%

577 (3)

2,279 (4)

5%

18,971 (92)

542,812
(90)

8%

17,468 (92)

51,249 (90)

7%

Women
Income Quintile †

Year of Cohort Entry ‡

Health care use §
Hospital discharge in the
two days prior
Cardiologist visits

Family physician visits

2
3

(Continued)
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Table 1. (Continued)
Unmatched
Chinese

Non-Chinese

N = 20,598
(%)

N = 605,175
(%)

0

16,813 (82)

414,679
(69)

1

2,569 (12)

2
3

Matched
Chinese

NonChinese

N = 19,033
(%)

N = 57,099
(%)

Standardized
Difference *

31%

15,551 (82)

45,896 (80)

3%

116,362
(19)

19%

2,364 (12)

8,053 (14)

5%

841 (4)

45,439 (8)

15%

7,82 (4)

2,287 (4)

1%

375 (2)

28,695 (5)

16%

3,36 (2)

863 (2)

2%

0

17,044 (83)

382,661
(63)

45%

15,750 (83)

46,171 (81)

5%

1

2,523 (12)

132,761
(22)

26%

2,340 (12)

8,202 (14)

6%

Standardized
Difference *

Hospitalizations

ER visits

2

678 (3)

47,828 (8)

20%

635 (3)

1,930 (3)

0%

3

353 (2)

41,925 (7)

26%

308 (2)

796 (1)

2%

283 (1)

23,632 (4)

16%

275 (1)

769 (1)

1%

Holter monitoring

1,067 (5)

43,793 (7)

9%

993 (5)

3,022 (5)

0%

Cardiac Stress Test

1,941 (9)

85,821
(14)

15%

1,823 (10)

5,191 (9)

2%

Echocardiography

3,503 (17)

13,4553
(22)

13%

3,160 (17)

9,211 (16)

1%

Coronary artery bypass
grafting (CABG)

Pulmonary function test

1,099 (5)

50,967 (8)

12%

1,049 (6)

3,087 (5)

1%

17,106 (83)

444,422
(73)

23%

15,722 (83)

47,540 (83)

2%

0

17,927 (87)

468,821
(77)

25%

16,652 (87)

49,963 (88)

0%

1

1,176 (6)

60,024
(10)

16%

1,108 (6)

3,314 (6)

0%

Cholesterol test
Co-morbidities ||
Charlson comorbidity index
#

2

742 (4)

38,237 (6)

13%

671 (4)

1,976 (3)

0%

3

753 (4)

38,093 (6)

12%

602 (3)

1,846 (3)

0%

0–4

10,312 (50)

260,430
(43)

14%

9,718 (51)

29,795 (52)

2%

5–9

8,697 (42)

272,385
(45)

6%

7,912 (42)

23,640 (41)

0%

10–14

1,497 (7)

65,918
(11)

13%

1,329 (7)

3,472 (6)

4%
1%

Johns Hopkins ACG score

15

92 (0.4)

6,442 (1)

7%

74 (0.4)

192 (0.3)

Chronic kidney disease

1,232 (6)

34,428 (6)

1%

732 (4)

2,196 (4)

0%

Major cancer **

1,297 (6)

61,331
(10)

14%

1,207 (6)

3,772 (7)

1%

Coronary artery disease††

3,309 (16)

175,078
(29)

31%

2,885 (15)

8,655 (15)

0%
(Continued)
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Table 1. (Continued)
Unmatched

Peripheral vascular disease

Chinese

Non-Chinese

N = 20,598
(%)

N = 605,175
(%)

Matched

Standardized
Difference *

Chinese

NonChinese

N = 19,033
(%)

N = 57,099
(%)

Standardized
Difference *

70 (0.3)

9,010 (1)

12%

53 (0.3)

380 (1)

6%

Diabetes‡‡

5,356 (26)

134,439
(22)

9%

4,813 (25)

14,583 (26)

1%

Chronic liver disease

1,263 (6)

12,219 (2)

21%

762 (4)

2,209 (4)

1%

Stroke/TIA

601 (3)

26,045 (4)

7%

559 (3)

1,329 (2)

4%

Heart failure

963 (5)

61,069
(10)

21%

834 (4)

2,544 (4)

0%

Sepsis

260 (1)

10,025 (2)

3%

220 (1)

576 (1)

1%

11,360 (55)

383,613
(63)

17%

10,291 (54)

31,381 (55)

2%

1,669 (8)

114,145
(19)

32%

1,587 (8)

4,356 (8)

3%

580 (3)

39,899 (7)

18%

508 (3)

1,564 (3)

0%

ACE Inhibitors

5,066 (25)

253,669
(42)

37%

4,838 (25)

14,004 (25)

2%

ARBs

5,445 (26)

95,466
(16)

26%

4,572 (24)

14,187 (25)

2%

Beta blockers

5,120 (25)

198,080
(33)

17%

4,616 (24)

13,421 (24)

2%

Calcium channel blockers

6,969 (34)

170,265
(28)

12%

6,047 (32)

18,584 (33)

2%

Loop diuretics

873 (4)

60,254
(10)

22%

718 (4)

2,378 (4)

2%

Potassium sparing diuretics

506 (2)

33,360 (6)

16%

477 (3)

1,475 (3)

0%

NSAIDs

3,216 (16)

108,378
(18)

6%

2,964 (16)

10,176 (18)

6%

Thiazide diuretics

2,576 (13)

121,829
(20)

21%

2,438 (13)

7,558 (13)

1%

Anticholinergics

543 (3)

27,886 (5)

11%

483 (3)

1,577 (3)

1%

Corticosteroids

892 (4)

29,894 (5)

3%

819 (4)

2,364 (4)

1%

Beta2-agonists

1,307 (6)

62,033
(10)

14%

1,203 (6)

3,757 (7)

1%

Amiodarone

150 (1)

9,320 (2)

8%

133 (1)

343 (1)

1%

Cyclosporine

13 (0.1)

209 (0.0)

1%

9 (0.0)

22 (0.0)

0%

Warfarin

796 (4)

47,906 (8)

17%

721 (4)

2,114 (4)

0%

Antidepressants

901 (4)

65,249
(11)

24%

846 (4)

2,570 (5)

0%

Levothyroxine

1,155 (6)

73,777
(12)

23%

1,098 (6)

3,330 (6)

0%

Quetiapine

67 (0.3)

3,803 (0.6)

4%

63 (0.3)

231 (0.4)

1%

Riseperidone

80 (0.4)

3,962 (0.7)

4%

69 (0.4)

239 (0.4)

1%

Olanzapine

67 (0.3)

3,252 (0.6)

3%

62 (0.3)

217 (0.4)

1%

Atorvastatin

10 [10–20]

10 [10–20]

10 [10–20]

10 [10–20]

Rosuvastatin

5 [5–10]

10 [10–10]

5 [5–10]

5 [5–10]

Hypertension
Angina
Arrhythmia
Medications §§

Statin daily dose, median [IQR], mg

(Continued)
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Table 1. (Continued)
Unmatched
Chinese

NonChinese

N = 19,033
(%)

N = 57,099
(%)

20 [10–40]

20 [10–20]

20 [10–20]

195 (0.9)

2,018 (0.3)

158 (0.9)

298 (0.5)

5 - <10 mg/day

3,594 (17)

43,137 (7)

3,075 (16.2)

8,350 (14.6)

10 - <15 mg/day

11,128 (54)

306,722
(51)

10,491 (55.1)

31,003 (54.3)

50 (0.2)

1,103 (0.2)

47 (0.3)

96 (0.2)

5,631 (27)

252,195
(42)

5262 (27.7)

17,352 (30.4)

Simvastatin

Chinese

Non-Chinese

N = 20,598
(%)

N = 605,175
(%)

20 [10–20]

Matched

Standardized
Difference *

Standardized
Difference *

Rosuvastatin starting dose ||||
0 - <5 mg/day

15 - <20 mg/day
20 mg/day

Abbreviations: TIA, transient ischemic attack; ACE, angiotensin-converting enzyme; ACG, adjusted clinical groups; ARB, angiotensin II receptor blocker;
NSAID, nonsteroidal anti-inﬂammatory drug; SD, standard deviation; IQR, interquartile range.
* Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups
divided by the pooled standard deviation; a value greater than 10% is interpreted as a meaningful difference between the groups.
† Income was categorized into ﬁfths of average neighborhood income on the index date.
‡ The date of cohort entry is also referred to as the index date.
§ Assessed by administrative database codes in the previous 1 year (unless otherwise speciﬁed).
|| Assessed by administrative database codes in the previous 3 years.
# Charlson comorbidity index [34, 35] was calculated using 3 years of hospitalization data. No prior hospitalizations received a score of 0.
** Major cancers include esophagus, lung, bowel, liver, pancreas, breast, male/female reproductive organs, as well as leukemia and lymphomas.
†† Coronary artery disease includes both diagnoses of angina and coronary artery revascularization.
‡‡ Assessed using prescriptions for diabetic medications.
§§ Assessed in the previous 120 days.
|||| Health Canada recommends a starting rosuvastatin dose of 5mg for individuals of Asian ethnicity.
doi:10.1371/journal.pone.0150990.t001

additional information became available questioning whether acute kidney injury is truly a
potential adverse event of a higher serum statin concentration [38, 39]. While liver injury is a
historic concern linked to statin therapy, recent studies have not confirmed this association
and regulatory bodies no longer identify it as a major concern [40, 41]; thus we decided a priori
not to include it as a study outcome. Since up to 25 unique diagnostic codes can be assigned
per hospitalization, patients with multiple diagnosis codes were accounted for in the assessment of each hospitalization outcome. However, the overall incidence is underestimated due to
a spectrum bias in hospital diagnosis coding, particularly for milder forms of conditions. For
example, the incidence of acute kidney injury can be underestimated up to five-fold when
assessed by diagnostic codes compared to laboratory values [27].

Statistical Analyses
We compared baseline characteristics of Chinese and non-Chinese using standardized differences [42]. This metric describes differences between group means relative to the pooled standard deviation and is considered a clinically meaningful difference if greater than 10%. We
used Cox proportional hazard regression analyses to estimate hazard ratios and 95% confidence intervals for each of our three outcomes (stratifying the models on matched sets). We
considered a two-tailed p-value of less than 0.05 to be statistically significant. In the follow-up
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Table 2. Statin-associated adverse outcomes in Chinese and non-Chinese (referent).
Number of Events (rate per 10,000 person-years)

Hazard Ratio (95% CI)

P-value

0.61 (0.28 to 1.34)

0.22

Chinese (n = 19,033)

Non-Chinese (n = 57,099)

Rhabdomyolysis *

16 (6.6)

79 (12.8)

Incident diabetes †

182 (267.5)

475 (252.4)

1.02 (0.80 to 1.30)

0.89

Acute kidney injury *

215 (89.2)

556 (90.8)

0.90 (0.72 to 1.13)

0.36

All-cause mortality ‡

324 (133.5)

965 (156.4)

0.88 (0.74 to 1.05)

0.17

Abbreviations: conﬁdence interval (CI)
* Outcomes assessed with hospital diagnosis codes. This underestimates the true event rate because these codes have high speciﬁcity but low
sensitivity.
† Diabetes diagnoses assessed with the Ontario Diabetes Database; only matched sets where none of the users had evidence of baseline diabetes were
included in this analysis (6,170 Chinese, 18,510 non-Chinese).
‡ All-cause mortality assessed with vital status ﬁeld of Registered Persons Database of Ontario.
doi:10.1371/journal.pone.0150990.t002

for these three outcomes, we censored the observation period at the time of death, statin discontinuation, or end of database records (March 31, 2013). In the primary analysis, statin discontinuation was defined by no evidence of a repeat prescription for the same statin within 30
days following the end of the previous prescription day supply. In our data sources, any deaths,
dispensed medications, and associated dates are recorded with high accuracy [22, 43]. We
repeated the primary analysis in subgroups defined by statin type (atorvastatin, rosuvastatin,
or simvastatin) and statin dose (high vs. low, as previously defined). We conducted all statistical analyses using SAS version 9.3 (SAS Institute, Cary, North Carolina).

Results
Baseline Characteristics and Follow-up Observation Period
Cohort selection is presented in Fig A in S1 File. We identified 625,363 new statin users aged
66 or older who were Chinese (n = 20,598) or non-Chinese (n = 604,765). After 1:3 matching
we retained 76,132 individuals (19,033 Chinese, 57,099 non-Chinese). The baseline characteristics of patients before and after matching are presented in Table 1. Before matching, those who
were Chinese exhibited significant differences in several baseline characterstics and were generally healthier compared to non-Chinese. While Chinese users were more likely to be prescribed
lower doses of rosuvastatin than non-Chinese (Table 1), more than half of Chinese were given
a starting dose higher than 5 mg per day for each year of the study period, which is contrary to
the recommendation from Health Canada and US Food and Drug Administration on rosuvastatin dosing in Asians released in 2005 (Fig B in S1 File). Matching resulted in two groups similar in age, sex, year of statin prescription, statin type, statin dose, baseline healthcare usage, and
multiple other baseline characteristics (Table 1).
The mean length of follow-up was 1.1 years and was similar between the groups (1.3 years
in Chinese, 1.1 years in non-Chinese; maximum 10.8 years). The total person-years of followup was 85,893 (24,259 Chinese, 61,634 non-Chinese). Statin discontinuation during follow-up
was lower for Chinese compared to non-Chinese (Table D in S1 File).

Outcomes
Study outcomes are shown in Table 2. Results are expressed in events per 10,000 person-years,
as well as in hazard ratios with patients of non-Chinese ethnicity serving as the referent group.
There was no significant difference between Chinese vs. non-Chinese in the risk of
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Fig 1. Subgroup analysis by statin type and dose for hospitalization with acute kidney. injury and a diagnosis of diabetes mellitus *†. * High dose
defined as 10 mg rosuvastatin, 20 mg atorvastatin, or 40 mg simvastatin; other values classified as low dose. † To comply with privacy regulations
numerators of 1 to 5 cannot be reported individually; for this reason we simply present the rate per 10,000 person-years, without additional information on the
number of events in each subgroup.
doi:10.1371/journal.pone.0150990.g001

hospitalization with rhabdomyolysis (hazard ratio [HR] 0.61, 95% confidence interval [CI]
0.28 to 1.34, p = 0.22), incident diabetes (HR 1.02, 95% CI 0.80 to 1.30, p = 0.89), hospitalization with acute kidney injury (HR 0.90, 95% CI 0.72 to 1.13, p = 0.36), or all-cause mortality
(HR 0.88, 95% CI 0.74 to 1.05, p = 0.17). We tested the proportionality assumption for all four
outcomes using time-dependent covariates in the Cox proportional hazards regression model.
The proportionality assumption was not violated for any of the outcomes, with all p-values
greater than 0.05. Additionally, we treated death as a competing risk and the results did not differ (Table E in S1 File). The results of subgroup analyses are shown in Fig 1. The risk of rhabdomyolysis was not assessed in subgroups because there were too few events for meaningful
analysis. Statin type and dose did not significantly modify the association between Chinese
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ethnicity and other outcomes. While there was a higher risk of incident diabetes in Chinese
patients taking a lower dose of rosuvastatin, the interaction of incident diabetes with higher
dose rosuvatatin was not statistically significant (p = 0.07).

Additional analyses
We conducted several additional analyses after knowledge of the primary results. First, if prescribing physicians titrated the dose of statin differently among Chinese and non-Chinese (to
clinical effects such as lipid level), this could abrogate the effect of ethnicity. To assess this we
examined the change in statin dose over the course of follow-up and expressed the change standardized to the initial dose ([final dose–initial dose in follow-up] / initial dose × 100). We
observed very little change in dose over the follow-up in both Chinese and non-Chinese
groups: the median (interquartile range) change in dose for both groups was 0 (0 to 0). We also
recorded the frequency and direction of dose changes within the cohort. Doses were stable in
84.0% in Chinese and 86.8% in non-Chinese, and increased in 11.5% of Chinese and 10.4% of
non-Chinese.
Second, although we observed no higher rate of statin discontinuation in Chinese versus
non-Chinese, it is possible that outpatient blood monitoring differed in the two groups and
influenced outcomes. Outpatient blood testing (which is a billable service to the universal provincial healthcare plan) is accurately recorded in our data sources (but values are not available).
We observed no significant difference between the two groups in the proportion of those with
creatine kinase, serum creatinine, serum glucose, or glycated hemoglobin testing during the follow-up periods (Table F in S1 File).
Third, in the primary analysis statin discontinuation was defined as absence of a prescription renewal within 30 days. In an additional analysis, we lengthened this definition to 100
days (which is the maximum day supply dispensed for a given prescription in Ontario). While
the mean follow-up increased to 2.5 years, there remained no higher risk of any of our study
outcomes in Chinese compared to non-Chinese (Table G in S1 File).

Discussion
Based on evidence of higher blood levels of a given statin in Asians, regulatory agencies such as
Health Canada and the US Food and Drug Administration recommend a lower dose of statins
for Asians compared to non-Asians. Although we showed that this recommendation is not frequently followed for Chinese patients in routine care, we observed no higher risk of statin toxicity in Chinese than matched non-Chinese older adults with similar indicators of baseline
health.
What is the basis for the recommended statin reduction in Chinese? Historically this was
attributed to the smaller body size and weight of Asians, as well as environmental and dietary
differences [3, 15], but pharmacokinetic modeling and clinical studies do not support these as
causative factors [44]. In recent years, a growing number of pharmacogenomic studies describe
significant differences between Chinese and non-Chinese in the frequencies of common
genetic polymorphisms linked to statin metabolism and transport [12]. For example, the frequency of the single nucleotide polymorphism (SNP) c.421 C>A in the ABCG2 gene (encoding
an efflux drug transporter) is much higher in the Chinese population (35% in Chinese versus
15% in Caucasians), which is associated with increased systemic exposure to rosuvastatin [44].
Interestingly, the presence of these genetic polymorphisms have also been linked to enhanced
lipid lowering effect, likely due to higher hepatic concentration of substrate statins [45].
A higher blood concentration with a given dose of statin in Chinese versus non-Chinese is
clear [13–15]. However, the risk of severe statin-associated adverse events associated with
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Chinese ethnicity remains unclear. In many large randomized controlled trials conducted in
both Asian and Western countries, amongst Asians there is no reported difference in the safety
or tolerability of a lower compared to higher dose of statin [3, 41, 46–48]. Rather, above-standard doses of statins provided additional cholesterol-lowering benefit in Asians [14]. Regulatory agencies should review available data, including findings from our study, to see if a change
in their statin dosing recommendations for people of Chinese ethnicity (and Asian ethnicity in
general) is warranted.
Our study’s findings must be interpreted in the context of its limitations. First, we identified
patients as Chinese or non-Chinese based on a list of uniquely Chinese surnames, rather than
self-reported ethnicity or genetic assessment. While the surname algorithm has been validated
and used in other health outcome studies, misclassification is possible. Second, some outcomes
were assessed with hospital diagnosis codes, and milder forms of adverse events may have been
missed. In HPS2-THRIVE, a large placebo-controlled trial of 25,673 high-risk patients, Chinese patients taking simvastatin 40 mg had a higher absolute risk of myopathy than patients in
Europe [49]. The outcome in HPS2-THRIVE included milder symptoms of myopathy, which
differs from the focus in this study (i.e. serious statin-associated adverse events that resulted in
hospitalization). Third, although our study outcomes were chosen based on evidence from previous literature, we appreciate that some outcomes remain controversial in their association
with statin use. Fourth, it is important to note that risk profiling based on ethnicity may not
generalize well to the care of an individual. Even within a population or ethnic group, there
exist a mixture of genotypes that serve as determinants of drug exposure and response [1].
Other inter-individual factors that are not well characterized may also affect overall drug
responses; for example in this study we did not have information on body composition or baseline laboratory values, nor did we account for dietary differences and the use of non-prescription drugs. Some common ingredients found in traditional Chinese medicine and the Chinese
diet, such as red yeast rice, may adversely interact with statins [50, 51]. Fifth, it is difficult to
objectively measure and compare drug compliance in retrospective observational studies.
While we were able to compare the rates of statin discontinuation (which was lower in Chinese
vs. non-Chinese), the exact reasons for discontinuation were unclear. Finally, we only studied
older adults given our available data. However, those who are younger (and often healthier)
would be expected to have lower rates of statin toxicity, making it more difficult to observe a
meaningful difference between Chinese and non-Chinese patients [52].

Conclusion
We observed no higher risk of serious statin toxicity in Chinese than matched non-Chinese
older adults with similar indicators of baseline health. Regulatory agencies should review available data to decide if a change in their statin dosing recommendations for people of Chinese
ethnicity is warranted.

Supporting Information
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death. Table F: Outpatient blood testing during follow-up. Table G. Statin-associated adverse
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